Allogeneic induced pluripotent stem cell (iPSC)-derived midbrain

Class

Allogeneic induced pluripotent stem cell (iPSC)-derived midbrain dopaminergic progenitor cell therapy, implanted bilaterally into the putamen via stereotactic neurosurgery

Pathway

Cell replacement of lost midbrain dopaminergic neurons to restore dopamine production and motor function in medication-resistant advanced Parkinson's disease

Notes

original target text: Allogeneic induced pluripotent stem cell (iPSC)-derived midbrain dopaminergic progenitor cell therapy, implanted bilaterally into the putamen via stereotactic neurosurgery

Parkinson's disease is caused by progressive degeneration of dopamine-producing neurons in a midbrain region called the substantia nigra, whose long projections normally supply dopamine to the putamen, a structure central to movement control. As these neurons are lost, dopamine levels fall and motor symptoms such as rigidity, slowness, and tremor emerge. Oral or infused dopaminergic medications compensate by supplying dopamine or mimicking its action, but in advanced disease this pharmacological approach becomes less reliable, with fluctuating benefit and worsening side effects. Cell replacement therapy takes a different approach: instead of continually supplementing dopamine from outside the brain, it aims to reintroduce cells capable of producing dopamine directly within the affected circuit. This is achieved by taking induced pluripotent stem cells (adult cells reprogrammed into an embryonic-like state), guiding them in the laboratory to become progenitors committed to a midbrain dopaminergic identity, and surgically implanting them bilaterally into the putamen. Because the cells originate from a donor rather than the patient (an allogeneic source), they can be manufactured in advance and used across many patients. The intent is durable, localized restoration of dopamine production and improved motor function in individuals whose disease no longer responds adequately to standard medication.